Parallel Advisors’s Oruka Therapeutics ORKA Stock Holding History

Parallel Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.6K	Buy	343 +323	+1,615%	+$21.5K	﹤0.01%	2398
2026 Q1	$981	Hold	20	–	–	﹤0.01%	3545
2025 Q4	$606	Hold	20	–	–	﹤0.01%	3374
2025 Q3	$385	Hold	20	–	–	﹤0.01%	3366
2025 Q2	$224	Hold	20	–	–	﹤0.01%	3410
2025 Q1	$205	Hold	20	–	–	﹤0.01%	3375
2024 Q4	$388	Hold	20	–	–	﹤0.01%	3274
2024 Q3	$490	Hold	20	–	–	﹤0.01%	3186
2024 Q2	$935	Hold	20	–	–	﹤0.01%	2977
2024 Q1	$429	Hold	20	–	–	﹤0.01%	3076
2023 Q4	$415	Hold	20	–	–	﹤0.01%	3086
2023 Q3	$490	Hold	20	–	–	﹤0.01%	3110
2023 Q2	$495	Hold	20	–	–	﹤0.01%	3102
2023 Q1	$486	Hold	20	–	–	﹤0.01%	3126
2022 Q4	$578	Hold	20	–	–	﹤0.01%	3011
2022 Q3	$1K	Hold	20	–	–	﹤0.01%	3053
2022 Q2	$1K	Hold	20	–	–	﹤0.01%	2890
2022 Q1	$1K	Hold	20	–	–	﹤0.01%	2873
2021 Q4	$1K	Hold	20	–	–	﹤0.01%	2987
2021 Q3	$1K	Buy	+20	New	+$739	﹤0.01%	2986

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Parallel Advisors's ORKA Position: Q2 2026 in Review

Parallel Advisors increased its Oruka Therapeutics (ORKA) stake by 1,615% in Q2 2026, buying an estimated $21.5K and bringing the position to 343 shares worth $32.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2398.

Parallel Advisors first reported a position in ORKA in Q3 2021 and has held it in 20 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

Parallel Advisors held 343 shares of Oruka Therapeutics worth $32.6K as of Q2 2026.
Parallel Advisors bought 323 Oruka Therapeutics shares in Q2 2026, an estimated $21.5K.
Oruka Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2398 holding.
Parallel Advisors first reported a position in Oruka Therapeutics in Q3 2021 and has held it in 20 quarters since.
255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.